News | August 01, 2023
Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
The product basket increased to 1800 medicines and 285 Surgical Equipment
More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Subscribe To Our Newsletter & Stay Updated
